Drawing for DUVEPRA

USPTO serial 76453235

DUVEPRA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
PIGNATELLO, ELIZABETH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with DUVEPRA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kevin M. Dugan

KEVIN M DUGAN MERCK & CO INCP O BOX 100WHITEHOUSE STATION, NJ 08889-0100UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of diabetes, cardiovascular diseases and disorders, anxiety, depression, diseases and disorders of the central nervous system, obesity, inflammation and inflammatory diseases, respiratory diseases and disorders, infectious diseases, urological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, and cancerACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 1, 2006MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 1, 2006ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 18, 2005EX5GSOU EXTENSION 5 GRANTED
Nov 7, 2005EXT5SOU EXTENSION 5 FILED
Nov 7, 2005EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 22, 2005EX4GSOU EXTENSION 4 GRANTED
Apr 22, 2005EXT4SOU EXTENSION 4 FILED
Apr 22, 2005MAILPAPER RECEIVED
Nov 5, 2004EX3GSOU EXTENSION 3 GRANTED
Oct 20, 2004EXT3SOU EXTENSION 3 FILED
Oct 20, 2004MAILPAPER RECEIVED
May 3, 2004CFITCASE FILE IN TICRS
Apr 26, 2004EX2GSOU EXTENSION 2 GRANTED
Apr 26, 2004EXT2SOU EXTENSION 2 FILED
Apr 26, 2004MAILPAPER RECEIVED
Nov 26, 2003EX1GSOU EXTENSION 1 GRANTED
Oct 31, 2003EXT1SOU EXTENSION 1 FILED
Oct 31, 2003MAILPAPER RECEIVED
Jun 24, 2003NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 1, 2003PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 12, 2003NPUBNOTICE OF PUBLICATION
Jan 30, 2003CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jan 28, 2003DOCKASSIGNED TO EXAMINER
Oct 25, 2002MAILPAPER RECEIVED
Oct 16, 2002MAILPAPER RECEIVED

Frequently asked questions

Related guidance